Hims & Hers: Top Pick For The Next Decade
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
Investment strategist picks 3 ‘new age' healthcare stocks to buy
Investment strategist Shay Boloor has highlighted three companies driving the “new age” of healthcare, making them must-watch opportunities for investors.
Bull of the Day: Hims & Hers Health (HIMS)
Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
Hims & Hers Health, Inc. (HIMS) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.04% change from the preceding trading day.
Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Hims & Hers Health Stock Couldn't Beat the Market Today
Hims & Hers Health (HIMS 0.37%) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous day was tempered by a lukewarm analyst note regarding the telehealth company's prospects.
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to platform.
Why Hims & Hers Health Stock Soared Tuesday
Shares of Hims & Hers Health (HIMS 5.01%) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed more modest movements.
Hims & Hers shares rise as company adds new weight-loss medications to platform
Hims & Hers Health is adding Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, to its platform. The company's GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
